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Abstract
Despite the use of highly active antiretroviral therapy (HAART), neuronal cell death remains a
problem that is frequently found in the brains of HIV-1-infected patients. HAART has successfully
prevented many of the former end-stage complications of AIDS, however, with increased survival
times, the prevalence of minor HIV-1 associated cognitive impairment appears to be rising among
AIDS patients. Further, HIV-1 associated dementia (HAD) is still prevalent in treated patients as
well as attenuated forms of HAD and CNS opportunistic disorders. HIV-associated cognitive
impairment correlates with the increased presence in the CNS of activated, though not necessarily
HIV-1-infected, microglia and CNS macrophages. This suggests that indirect mechanisms of
neuronal injury and loss/death occur in HIV/AIDS as a basis for dementia since neurons are not
themselves productively infected by HIV-1. In this review, we discussed the symptoms and causes
leading to HAD. Outcome from this review will provide new information regarding mechanisms of
neuronal loss in AIDS patients.
Definition and causes
Dementia cannot be considered as a disease by itself but
it is the term used to describe a set of symptoms resulting
from damages and disorders affecting the brain. These
symptoms can be caused by a multitude of diseases and
depend upon the specific brain regions affected. These
symptoms appear as a variety of cognitive, behavioral,
affective, motor, and psychiatric disorders. Dementia can
be caused by a variety of diseases, known as neurodegen-
erative diseases resulting from protein aggregation in the
brain [1]. These diseases include Alzheimer's, Lewy bod-
ies, Huntington and Parkinson [1]. Infectious diseases
affecting the central nervous system (CNS) may lead to
dementia. These infections can be caused by different
agents such as: abnormal protein in prion diseases (Creut-
zfeldt-Jakob disease), bacteria in syphilis and borrelia,
parasites in toxoplasmosis, cryptococcosis and neurocyst-
icercosis [2], however viral agents are the leading cause of
infection related dementia. Among the viruses infecting
the brain, human immunodeficiency virus type 1 (HIV-1)
is the most common cause of dementia, other CNS viral
infection implying herpes simplex virus type I, Varicella
zoster virus, cytomegalovirus, Epstein-Barr virus cause
encephalitis and severe brain dysfunction. The collection
of viral agent infecting the CNS and producing viral
encephalitis includes also arboviruses, rabies viruses,
polyomaviruses and enteroviruses [3]. Finally, dementia
could also be caused by vascular disorders (e.g. multiple-
infarct dementia), drug addiction, hydrocephalus, and
injury or brain tumors [4,5]. Despite the variability of
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symptoms with the disease causing dementia there is
overlap, potentially because of the involvement of com-
mon neural pathways and the nature of the damage. How-
ever, the time of appearance, the severity, and type of
symptoms allow, in most cases, to help making the dis-
tinction between diseases. There are however cases of
coexistence of clinical and/or pathological features where
more than one disease is manifested in one individual,
and which might be due to co-occurrence of common dis-
eases within the individual [6]. In elderly populations,
Alzheimer's disease is the most frequent cause of demen-
tia, while neuroAIDS is the major cause of dementia in
younger population (less than 60 years old). In the United
States, HIV-1 infection is the most common cause of
dementia in young adults [7,8]. Since many diseases and
viral infection lead to dementia, we focused our review on
HIV-1 associated dementia, its symptoms and causes.
Neuropathology of AIDS
HIV-1 is the causative agent of acquired immunodefi-
ciency syndrome (AIDS), which is a multi-system disorder
including the CNS. Neurological impairment affects
approximately 60% of HIV-infected patients [9]. HIV-1
enters the CNS at the early phase of infection [10], persists
in that system for decades and induces multiple symp-
toms of motor, cognitive dysfunction and behavioral
changes. Many factors can contribute to the neuropathol-
ogy of AIDS, particularly opportunistic brain infections
such as cryptococcus, Toxoplasma gondii, JC virus,
cytomegalovirus, Epstein-Barr virus, Varicella zoster virus,
and human herpes virus type 6 [2]. In the absence of
opportunistic infections, major clinical symptoms include
impaired short term-memory coupled with reduced abil-
ity of mental concentration, leg weakness, slowness of
hand movement and gait as well as depression [11,12].
These symptoms are often accompanied by behavioral
symptoms such as personality changes, apathy and social
withdrawal. The terms AIDS dementia complex (ADC),
and HIV-1 associated dementia (HAD), are used to
describe these neurological and psychiatric symptoms
caused by HIV-1 infection [11,12]. An effective therapy for
HIV/AIDS became available in 1995, generally known as
highly active antiretroviral therapy (HAART). This therapy
consists of a combination of at least three drugs blocking
different aspect of viral replication, markedly reverse tran-
scriptase inhibitors and protease inhibitors. HAART has
the capability of restoring immune function; suppressing
viral replication to nearly undetectable level, conse-
quently ameliorating HIV related symptoms in the CNS
and preventing opportunistic conditions. Before the intro-
duction of HAART, nearly 30% of the infected population
developed HAD at the late stage of HIV/AIDS. With the
use of HAART this rate is reduced to 10% [13]. However,
a more subtle form of CNS dysfunction, known as minor
cognitive motor disorder (MCMD), has become more
common in HIV patients [14]. In this condition, memory
loss and the reduction of cognitive and computational
functions are much less pronounced. Recently it has been
estimated that nearly 30% of adults infected with HIV are
affected by MCMD. However, HAD is far from being con-
trolled by HAART; in the setting of HAART the HIV-1
infection become chronic and recent studies show a rise in
the incidence of the HAD [3], it is noteworthy that HAART
is not designed to target the inflammatory cascade under-
lying the HAD. In addition some of the HIV-1 infected
population develop resistance against HAART and an
important fraction of AIDS patients, especially in develop-
ing countries, have not access to HAART. In the United
States, HIV-1 infection is the most common cause of
dementia in young adults [7,8].
The HIV-1 associated neuropathology is characterized by
the infiltration of macrophages into the CNS; the forma-
tion of microglial nodules; and multinucleated giant cells
which result possibly from virus-induced fusion of micro-
glia and/or macrophages in central white and deep gray
matter; astrocyte activation and damage; neuronal loss
particularly in hippocampus, basal ganglia and caudate
nucleus. In addition, a variable degree of white matter
pathology with evidence of broad range of myelin damage
ranging from pallor to widespread breakdown and loss
leading to accumulation of lipid macrophages in extreme
cases, with axonal damage in the latter cases, and the pres-
ence of HIV-1 in the cerebral spinal fluid (CSF) has been
reported [13,15]. These neuropathological consequences
of infection are collectively termed HIV-1 associated
encephalitis (HIVE).
Clinical observations, using MRI, confirm that HIV infec-
tion is associated with progressive cortical atrophy within
the gray and white matter in the brain, particularly in the
later stage of the disease [16-19]. These studies report a
correlation between the deterioration of cognitive func-
tion and the reduction in volume of certain brain struc-
tures including the basal ganglia and caudate nucleus.
Volumetric MRI analysis has shown that cortical atrophy
associated with HIV infection might be caused by neuro-
nal loss and demyelination. The degree of atrophy is cor-
related to the degree of cognitive motor dysfunction in
both cross-sectional and longitudinal cohorts [16,19,20].
Quantitative MRI shows a correlation between cerebral
atrophy and neuropsychological performance. Over time,
the correlation persists between an increase in atrophy
and worsening in certain cognitive functions [16].
Viral entry and replication
HIV-1 targets the lymphoid and nervous systems by
infecting cells containing major HIV-1 receptors, CD4 and
CD8, and various chemokine receptors considered as
HIV-1 co-receptors. These receptors help the attachmentRetrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
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of the virus to the cell and the fusion of their membrane
resulting in the entry of the virus into the cell [21]. HIV-1-
specific CD4+ helper T lymphocytes and CD8+ cytotoxic T
lymphocytes have been detected within 4-6 weeks after
HIV-1 inoculation [22]. Infected CD4+ T cells and mono-
cytes, which circulate in the blood, are the potential
source of CNS infection [14]. The mechanisms of entry of
these cells into the CNS are discussed in the next section.
Among the chemokine receptors expressed on human
cells, CXCR4 appears to be the most important for HIV-1
entry into lymphocytes and CCR5 for monocytes, macro-
phages and microglia [23]. Because of the variability of
HIV-1 phenotypes, these strains of virus are defined by
their usage of the CCR5 or CXCR4 co-receptors, and des-
ignated as R5- and X4- viruses respectively [23]. Following
entry into the cell, the virus undergoes reverse transcrip-
tion of its RNA genome to form a double-stranded DNA,
a pre-integration complex of viral DNA with integrase and
other viral protein including Vpr and matrix protein is
transported to the nucleus. The pre-integration complex
facilitates the integration of the HIV-1 DNA genome into
host chromatin. The integration of viral DNA into the
host cell genome generates the provirus that allows the
production of HIV-1. In addition, high levels of viral DNA
remain non-integrated in the nucleus and are capable of
directing expression of viral transcript [24-26]. The gener-
ation of infectious virus particles involves the production
of viral transcripts and proteins and viral assembly, release
and maturation. During the production phase, first the
vial regulatory factors Nef, Tat and Rev are generated, and
viral structural proteins and the RNA genome are pro-
duced in a later phase. In the assembly phase, Gag and
Gag-Pol Polyproteins, envelope proteins and viral RNA
genomes are assembled into immature virus particles at
the cell membrane and released from the host cell. The
cleavage of Gag and Gag-Pol Polyproteins by the HIV-1
protease results in the production of mature virus [27-29].
The intracellular environment plays a major role in HIV-1
virus replication [30]. HIV-1 infected cells are classified as
highly active producers and low or non-producers of
viruses, known as "productive" and "restricted" infection,
respectively. Both types of infections occur in the CNS.
Productively infected cells support productive viral repli-
cation and participate in the transmission of the infection
and the rapid evolution of viral genome in the human
host and die ultimately. Restricted infection is only detect-
able by highly sensitive methods showing the presence of
HIV-1 DNA or RNA. However, in the absence of structural
viral protein expression, it has been reported that acces-
sory/regulatory protein such as Rev and Nef have been
expressed [31,32]. Restrictedly infected cells are permis-
sive to infection by HIV-1 strains but are refractory to effi-
cient virus expression, they restrict the HIV-1 replication
and survive as virus reservoir in which replication-compe-
tent viral genome persists. The restricted infection implies
that efficient HIV-1 replication might be blocked at differ-
ent stage of virus life cycle, including virus entry, reverse
transcription, nucleo-cytoplasmic HIV-1 RNA transport,
translation of viral DNA, and maturation of progeny vir-
ion. Studies of different astrocytes cell lines, which are
known to be non-productively infected, demonstrated a
cytoplasmic presence of Rev up to seven time more ele-
vated than in productively infected cells [33,34]. These
observations lead to the hypothesis that restricted HIV-1
production in astrocyte may be partly due to a cell deter-
mined block in nucleo-cytoplasmic Rev shuttling causing
the nuclear retention of Rev-dependent HIV-1 mRNA
classes where they are degraded [35,32]. Changes in cell
environment, like the elevation in the level of cytokines
such as TNF-α and IL-1β, might reactivate virus produc-
tion [10,36].
Neuroinvasion of HIV-1
The role of blood-brain barrier (BBB), which is a continu-
ous cellular layer of tightly linked brain microvascular
endothelial cells, is to separate the CNS from the periph-
ery (Figure 1). The BBB is selectively permeable and regu-
lates the trafficking of cells and substances between the
brain parenchyma and the bloodstream [14,15]. The CSF
is also separated from the periphery by the blood-CSF bar-
rier of the choroids-plexus epithelium. In order to enter
the brain, HIV-1 must cross the BBB using mechanisms
that remain unclear. Numerous studies have used animal
models and in vitro experimentation to understand the
mechanisms of HIV-1 introduction into the CNS through
BBB [14]. The generally accepted model, with most com-
pelling evidence, is the "Trojan Horse hypothesis"
[37,38]. According to this model, HIV-1 and other lentivi-
ruses enter the CNS as a passenger in cells trafficking to
the brain (Figure 1). Many CD4+ cells, such as T cells and
monocytes are infected by HIV-1, these cells circulate in
the blood and can cross the BBB and propagate the infec-
tion within the CNS [37]. This model was confirmed by in
situ  hybridization and immunohistochemical analysis
that brought evidence of virus accumulation in perivascu-
lar regions [39-41]. Though BBB abnormalities due to
HIV-1 infection have been observed, however, the mech-
anisms of endothelial cells infection and the expression of
conventional HIV receptors in these cells remain a contro-
versial issue. Although some studies suggest that human
brain microvascular endothelial cells lack CD4 receptors
[42], other studies have found that CD4 was expressed in
isolated endothelial cells and microvessels of HIV-1
infected children's brains [43,44], moreover the expres-
sion of HIV-1 co-receptors such as CCR5 and CXCR4 have
also being reported on isolated primary human brain's
microvascular endothelial cells [45]. An alternative
hypothesis of HIV-1 neuro-invasion proposes the entry of
free HIV-1 by migration between or, transcytosis ofRetrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
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endothelial cells [10,14,46,47]. Theoretically all the main
cell types of the CNS, astrocytes, oligodendrocytes, neu-
rons, perivascular macrophage and microglia, can be
infected by HIV-1 since they possess the receptors and/or
co-receptors for HIV-1 entry, but only the latter two are
the most commonly infected cells by HIV-1 [14].
Macrophage and microglia
Perivascular macrophage, microglia, and astrocytes are
the cells coming into direct contact with infected cells in
perivascular region. The two first types of cells are the res-
ident immunocompetent cells of the brain and their
major role is to respond to all types of insults. Peripheral
macrophage population is replenished through the
lifespan with a relatively fast turnover, probably because
of its proximity to the interface with the periphery. This
replenishment that takes place by the migration of mono-
cytes into the CNS has the side effect of opening the door
to the intracellular pathogen. As the monocytes take resi-
dency in the CNS they differentiate into macrophages.
Microglia and monocyte-derived macrophage are consid-
ered to be the main sources of productive HIV-1 infection
in the brain [48,49]. One of the characteristics of HIVE is
the presence of multinucleated giant cells expressing CD4.
These cells are assumed to be infected monocytes differen-
tiated into macrophage after entering the brain or arising
from the fusion of infected microglia [50]. It has been
shown that in the primate Simian Immunodeficiency
Virus (SIV) model the spread of the virus from perivascu-
lar cells to the parenchymal microglia does not occur [51],
HIV-1 neuroinvasion Figure 1
HIV-1 neuroinvasion. 1) According to the "Trojan Horse hypothesis" entry of HIV-1 into the brain takes place by the migration 
of infected monocytes which differentiate into perivascular macrophage. 2) The passage of infected CD4+ T cells can be 
another source of infection in the brain. Other probable causes of CNS infection might be: 3) the direct entrance of the virus 
or 4) entrance of HIV-1 by transcytosis of brain microvascular endothelial cells. Once the virus is in the brain it infects produc-
tively macrophages and microglia. Astrocyte infection is known to be restricted. The infection of oligodendrocytes and spe-
cially neurons is questionable.Retrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
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however this issue remains controversial and has not been
confirmed for SIV and HIV-1. In contrast, many studies
suggest the opposite for HIV-1. Immunostaining has
revealed HIV-1 infection of parenchymal microglia, in
some cases the infection is widespread, but in other cases
it is restricted to the perivascular compartment [52]. It is
not clear whether the HIV-1 immunopositive microglia
consists of an influx of infected cells from the blood or
results from long-term infection in the CNS. In-vitro stud-
ies have demonstrated that HIV-1 replication takes place
in primary microglia isolated from adults [53,54], infants
[55], and fetal brain [56,57]. HIV-1 infection in Microglia
can be associated with cytopathology, including the for-
mation of syncytia [54]. The study of the course of HIV-1
infection in purified primary cultures of human microglia
shows that productive infection was more readily estab-
lished by R5-tropic strains of HIV-1 than by an X4-tropic
strain [55]. Microglial cells similar to macrophage express,
CD4/CCR5, major receptors/co-receptors used by HIV-1
[58-60]. Other chemokine receptors, e.g. CCR3, CCR2b,
CCR8, CXCR6, and CX3CR1, are also expressed by these
cells but less efficiently used by HIV-1 [60,61]. In vitro
studies have shown that long-lived mixed microglial cul-
tures isolated from human brain, when infected with R5
HIV-1, retain replication competent viruses for up to 2.5
months with low level virus replication, providing an acti-
vating condition can result in productive virus replication
[62].
Astrocytes
Astrocytes do not have the CD4 receptor, which plays an
important role in the infection of immune system cells,
but they express CXCR4 and possibly other HIV-1 co-
receptors including CCR5 [32]. However, several studies
have reported the infection of astrocytes by HIV-1
although the mechanisms of viral attachment to astro-
cytes remain unclear. Immunopositivity of astrocytes for
HIV-1 structural proteins has occasionally been reported
[35]. However, in situ hybridization, or in situ PCR have
revealed the presence of HIV-1-specific nucleic acids in
astrocytes [40,63,64]. Other studies reported the presence
of the viral DNA and HIV-1 Nef protein in astrocytes [65].
HIV-1 infection was studied using primary human fetal
astrocytes and tumor derived cell lines, several HIV-1 iso-
lates, namely X4-using T-cell line adapted (NL4-3, 1 MB,
SF2), R5-using, macrophage tropic (JR-FL, SF162) strains
and primary isolates from blood [32,66,67]. The partici-
pation of astrocytes in productive infection has not been
reported, though virus production in persistently infected
cells can be transiently activated by the treatment with
inflammatory cytokines [32,66,67].
Oligodendrocytes
In vivo, Oligodendrocytes infection by HIV-1 remains con-
troversial. While some studies have detected viral nucleic
acids by in situ PCR [63,64], other studies have reported
the absence of HIV-1 markers in oligodendrocytes [33]. In
vitro  studies, using human oligodendrocytes indicates
restricted infection by R5 and X4 strains of the virus [68].
Some studies have reported a reduced expression of spe-
cific oligodendrocyte markers, such as MBP and CNPase,
in mice expressing HIV-1 Nef [69]. Oligodendrocytes do
not possess CD4 receptors and the mechanisms of their
potential infection remain unclear.
Neurons
Most studies have indicated an absence of in vivo infection
in neurons, however a few studies have reported the pres-
ence of HIV-1 DNA and proteins in neurons [63,64]. It
has been suggested that the detection of infected neurons
in the brain might be complicated by the loss of the
infected neuronal populations [14]. In vitro studies have
reported restricted infection of primary neurons [70], and
neuronal cell lines by X5 and R4 viruses [71,72].
Mechanisms of neurodegeneration in HIV-
associated dementia
The absence of significant neuronal infection by HIV-1
contrasts with the extensive neuropathological damage
observed in HAD, therefore different mechanisms involv-
ing the HIV-1 infection of perivascular macrophages,
microglia, and possibly astrocytes might play the princi-
pal role in neuronal injury and the disruption of normal
neurological function. The neuronal injury can result
from a direct mechanism by interaction with viral pro-
teins, such as gp120, Tat (Transcriptional transactivator)
and Vpr (viral protein R) produced by infected cells, or by
an indirect effect resulting from the inflammatory process
involving activated monocytes, macrophages and astro-
cytes (Figure 2).
HIV-1 Tat
The viral protein Tat, which is mainly active in the
nucleus, was shown to be secreted at high-level in vitro.
Secreted Tat can cause direct or indirect injury to neurons,
therefore it has been suggested that Tat contributes to
HAD neuropathogenesis [73]. The neurotoxicity of Tat
involves prolonged increase in intracellular calcium fol-
lowed by an increase of reactive oxygen species and cas-
pase activation of apoptotic pathway [73,74], in addition
it has been shown that the up-regulation of caspase-8 by
HIV-1 Tat expression in CD4 T cell lines may contribute to
the increased apoptosis and sensitivity to apoptotic sig-
nals [75]. Tat is shown to alter the expression distribution
of tight junction proteins, claudin-1 and claudin-5 in cer-
ebral microvascular endothelial cells [76]. By affecting
endothelial permeability, Tat contributes to the disrup-Retrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
Page 6 of 11
(page number not for citation purposes)
tion of the BBB that leads to infiltration of inflammatory
cells into the CNS [76,77]. Further, Tat participates in the
HAD associated inflammatory cascade by promoting
TNF-α and interleukin IL-1 production by monocytes and
macrophages, and stimulates the production of several
cytokines and chemokines, including IL-8, RANTES,
MCP-1 and TNF-α in astrocytes, which leads to neurotox-
icity [73].
HIV-1 Vpr
The regulatory protein Vpr might also be a player in the
direct mechanism of neuronal damage (reviewed in [78]).
Vpr has been found in the CSF of HAD patients [79]. Vpr
induces cell cycle arrest at G2/M phase, which leads to cell
death [80], a recent model of Vpr mediated induction of
apoptosis, in CD4+ cells, proposes that Vpr expression
activates cancer-associated protein BRCA1 and up-regu-
Mechanism of neuropathogenesis Figure 2
Mechanism of neuropathogenesis. Two components of this mechanism are: A) the direct effect of the HIV-1 infection, including 
HIV-1 proteins and B) the indirect consequence of infection comprising the secretion of cytokines and neurotoxins. The 
infected macrophages and microglia participate actively in the neurodegeneration by: 1) shedding viral proteins and 2) releasing 
significant amount of cytokines and neurotoxins into the CNS. 3) Tat and TNF-α contribute to the disruption of the blood 
brain barrier, which in turn become more permeable to infected monocytes and cytokines present in the periphery. The 
secreted pro-inflammatory cytokines activates 4) microglia and 5) astrocytes which in turn secrete neurotoxins, moreover the 
alteration of astrocytes function results in an increase in the level of neurotoxicity in the brain. 6) Multifactorial neuronal injury: 
neurotoxins released from several sources, as the direct and indirect consequences of HIV-1 infection, lead to neuronal injury.Retrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
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lates the expression of DNA damage-45 protein α
(GADD45α) [81]. It has been reported that Vpr also alters
mitochondrial permeability, which can cause cytochrome
c release and eventually lead to apoptosis [82], however
this issue needs to be confirmed. Furthermore, another
study of Vpr-mitochondria interaction has shown that Vpr
targets HAX-1, an antiapoptotic mitochondrial protein,
Vpr associates physically to that protein and Vpr over-
expression leads to dislocation of HAX-1 from its normal
mitochondrial residence and causes mitochondrial insta-
bility and apoptosis [83]. Recent studies have demon-
strated that both intracellular and extra cellular Vpr can
induce apoptosis of human neuronal-precursor cells and
mature, differentiated neurons by increasing the activa-
tion of caspase-8 [84]. Finally, Tat and Vpr mediated-
apoptosis could increase significantly by co-exposure of
cells to ethanol [84,85].
HIV-1 gp120
HIV-1 envelope glycoprotein gp160 is shown to have neu-
rotoxic effect. This protein can be cleaved into two prod-
ucts that remain non-covalently associated: gp120 and
gp41. The soluble viral envelope protein gp120, which is
released in large quantities by HIV infected cells, might be
involved in neuronal injury. The toxic effect of gp120 on
neuronal population was demonstrated by many studies
[86,87], dopaminergic neurons might be more suscepti-
ble to gp120 neurotoxicity [88]. It has been shown that
transgenic mice overexpressing gp120 had neuropatho-
logical features similar to abnormalities in brains of HAD
patients [89]. Neurodegeneration induced by gp120 can
be direct through interaction with NMDA (N-Methyl-D-
Aspartate) receptor or indirect by interaction with chem-
okine receptors [90,91]. Further, it has been shown that
the presence of p53 is essential for gp120-induced neuro-
nal apoptosis [92]. Furthermore, both gp120 and Tat have
been shown to disrupt neuronal calcium homeostasis by
perturbing calcium-regulating systems in the plasma
membrane and endoplasmic reticulum, which leads to
neuronal death [93]. Recently, it has been described that
SDF-1α and gp120 induced a similar level of neuronal
apoptosis, but by activating different intracellular path-
ways. SDF-1α enhanced NMDA activity indirectly via Src
phosphorylation, whereas gp120 probably activated the
NMDA receptor directly and phosphorylated JNK [94].
These results are in accord with other studies, where
gp120 was shown to induce neuronal dysfunction and
death through actions at p38 mitogen-activated protein
kinase, while Tat kills neurons through actions that are
independent of p38 or c-jun-N-terminal kinase mitogen-
activated protein kinase, or through the concurrent activa-
tion of multiple pro-apoptotic pathways [95].
Some chemokine receptors are considered to act as a
direct conduit for gp120 neurotoxicity, whereas others
can have neuro-protective effects [49,87]. The role of
CXCR4 in the gp120 mediated neurotoxicity can be direct,
through the activation of neuronal receptors by gp120, or
indirect through the stimulation of glial cells leading to
release of neurotoxic factors. Several studies have shown
that T tropic (X4) and dual tropic (X4/R5) gp120 induce
apoptosis in primary neurons and in neuronal cell lines
[96,97]. In contrast to the neuroprotective role of
RANTES/CCL5 and MIP-1β against gp120, in mixed neu-
rons/glial cultures, it has been shown that SDF-1α/CXCL2
not only failed to provide neuro-protection from gp120,
but induced apoptosis in its absence [49]. Beside its direct
neurotoxic effect, the viral protein gp120 has a significant
role in the indirect mechanisms of neurodegenertion by
acting on macrophages, microglia or astrocytes [87,96].
Gp120 interaction with astrocytes stimulates the induci-
ble form of nitric oxide synthase and increases the release
of arachidonic acid from astrocytes, which leads to the
inhibition of glutamate uptake by astrocytes and neurons
[98]. As a result the extracellular concentration of gluta-
mate increases and could lead to neurotoxicity via activa-
tion of excitatory amino acid receptors on neurons [73].
By acting on monocytes and macrophages gp120 induces
the production of TNF-α, IL-1 and arachidonic acid
metabolites which are implicated in HIV-1 neuropatho-
genesis.
HIV-1 associated chemokines
The chemokines and their receptors are considered to be
involved in the pathogenesis of a number of neurological
diseases including HAD, multiple sclerosis, Alzheimer's
disease, and prion infection. The over-expression of some
chemokines in specific brain areas might contribute to the
pathological condition. The chemokines and their recep-
tors are the gate of entrance of HIV into the CNS [99].
Because of the alterations and abnormalities in the expres-
sion of chemokines and their receptors in the HIV infected
CNS cells, and the role of chemokines in several neurode-
generative diseases, they have been the focus of attention
in studies of HAD pathogenesis [100]. All members of the
CXCR family are expressed, mainly by neurons, in the
brains of individuals affected by HAD [101]. Semiquanti-
tative immunohistochemical analysis of the brain of HIV-
1 infected individual, investigating the expression of four
HIV-1 co-receptors CCR2, CCR3, CCR5 and CXCR4 has
shown that the hippocampal neurons were positive for
CCR2, CCR3, and CXCR4 [102]. In other regions of the
brain, neurons, as well as glial cells were positive for
CCR2, CCR3, and CXCR4, whereas only primary micro-
glial cells were positive for CCR5. The areas of highest
expression seem to be subcortical regions and the limbic
system. The role of limbic system in memory and other
cognitive functions, and the presence of CXCR4 on a sub-
population of neuron from this system might explain cog-
nitive and memory dysfunction in HAD. The presence ofRetrovirology 2006, 3:28 http://www.retrovirology.com/content/3/1/28
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chemokines and chemokine receptors increases in the
brain tissues of HIVE patients, particularly in areas of neu-
roglial reaction, where they might be involved in the
recruitment of inflammatory infiltrates and formation of
microglial nodules. The levels of expression of CCR1,
CCR3, CCR5 and CXCR4 are especially elevated in the
microglial nodules [59,103]. Moreover, CCR3 and
CXCR4 are highly expressed in the pyramidal neurons of
hippocampus, and in the enthorinal cortex for CCR3.
Compared to AIDS patients without HAD, the brain tissue
of patients with HAD shows an over-expression of CX3C
chemokine, fractalkine/CX3CL1 [104,105]. The upregula-
tion of fractalkine/CX3CL1 was found in neurons in
brains of pediatric patients [104]. In contrast, fractalkine/
CX3CL1 was found to be over-expressed in astrocytes in
adult patients [105]. The level of chemokines in the CSF
of HIV-infected patients with and without HAD has been
determined in several studies. The results show that CSF
chemokine concentration of MCP-1/CCL2, MIP-1α/
CCL3, MIP-1β/CCL4, RANTES/CCL5, IL-8/CXCL8 and
fractalkine/CX3CL1 is positively correlated with the sever-
ity of dementia and the viral load, indicating HIV induced
brain damage. The role of CCR5, which is expressed by
neurons, microglia and astrocytes in the brain, seems
more controversial in the pathogenesis of HAD. The acti-
vation of CCR5 by RANTES or MIP-1α/β, in in-vitro stud-
ies, is shown to offer neuro-protection against gp120
induced apoptosis [87,106]. However, in vitro observa-
tions indicate that neuro-virulent strains of HIV are essen-
tially M-tropic with increased affinity for CCR5 [107]. It
has also been shown that CCR5 activation via its specific
ligand induced apoptosis in neuroblastoma but not in
fibroblast cell lines [108]. Therefore, it can be assumed
that CCR5 might act as a death receptor in neurons and
participate in HIV-1 induced neuropathology.
In brief, cognitive, motor decline and behavioral disorders
in HAD can be explained by significant neuronal cell
death that has been reported as a consequence of HIV-1
infection in the brain [109,110]. However, very few trace
of infection has been found in neurons of HAD patients'
brains. Therefore the neuronal loss might be caused by the
release of neurotoxic factors by HIV infected microglia
and astrocytes and/or by neurotoxic HIV-1 proteins.
The inflammatory cascade
The indirect mechanisms of AIDS neuropathogenesis also
include the effect of the inflammation resulting from the
modification of extracellular secretory functions of micro-
glia and brain macrophages and inflammatory cytokine
production in the CNS (Figure 2). Following entry to the
brain, monocytes, lymphocytes, activated macrophage,
microglia and astrocytes release cytokines, reactive oxygen
species, and other neurotoxins that disrupt normal cellu-
lar functioning, modify neurotransmitter action, and may
lead to leukoencephalopathy and ultimately neuronal
apoptosis [111,112]. Some of these neurotoxins include
TNF-α, arachidonic acid, platelet activating factors (PAF),
nitric oxide (NO), and quinolinic acid (QUIN). NO is
synthesized by endothelial cells, macrophages and neu-
rons and might be associated with the NMDA type gluta-
mate associated neurotoxicity. A high level of inducible
NO synthase has been found in the brain of HAD patients
[113]. In HIV-1 patients who also are/were drug addicted
(e.g. cocaine, heroine), a 40-fold increase in expression of
NO synthase in neurons of temporal lobes was reported
[114]. TNF-α is released by HIV-1 infected macrophage
microglia and particularly affects oligodendrocytes [115].
It has been shown that TNF-α mRNA level in the subcor-
tical regions of HAD patients' CNS are higher than in
AIDS patients without neurological symptoms [116]. In
addition, TNF-α can damage the BBB, as shown in an in-
vivo model, which could facilitate entry into the brain of
HIV-1 protein(s) and cytokines secreted in the periphery
[117]. Not only the level of pro-inflammatory cytokines,
such as TNF-α, IL-1 and IFN-γ, anti-inflammatory
cytokines including TGF-β and IL-6, and soluble cytokine
receptors is elevated in AIDS patients, but the cytokine
production is correlated with the gravity of the neuropa-
thology [118,119].
This review is a summary of some of the current data sup-
porting both the direct and indirect mechanisms by which
neuronal death may occur during infection with HIV-1.
HAD is a complex phenomenon, which could be the
result of several mechanisms caused by players using dif-
ferent pathways. Some of these players, mechanisms, and
pathways were mentioned in this review and some of
them are either un-identified or left out e.g. MCP-1, cellu-
lar proteins involved in the regulation of HIV-1 gene
expression, Ca++  induction, HIV-1 activated apoptotic
programs (reviewed in [120]). Finally, more strategies are
needed for treating or preventing HAD by targeting spe-
cific neurotoxic mechanisms used by the above-men-
tioned viral proteins.
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